Cite
HARVARD Citation
Ruhlmann, C. et al. (n.d.). Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet oncology. 17 (4), pp. 509-518. [Online].